IFG Advisory LLC Raises Stock Holdings in CVS Health Corporation $CVS

IFG Advisory LLC lifted its holdings in CVS Health Corporation (NYSE:CVS) by 222.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,101 shares of the pharmacy operator’s stock after purchasing an additional 31,116 shares during the quarter. IFG Advisory LLC’s holdings in CVS Health were worth $3,400,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of CVS. Atlantic Union Bankshares Corp raised its position in shares of CVS Health by 54.8% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 98,295 shares of the pharmacy operator’s stock valued at $6,780,000 after buying an additional 34,804 shares in the last quarter. Resona Asset Management Co. Ltd. increased its stake in CVS Health by 1.3% during the second quarter. Resona Asset Management Co. Ltd. now owns 461,922 shares of the pharmacy operator’s stock worth $31,832,000 after acquiring an additional 5,714 shares during the last quarter. Golden State Wealth Management LLC raised its position in CVS Health by 318.6% during the second quarter. Golden State Wealth Management LLC now owns 1,218 shares of the pharmacy operator’s stock valued at $84,000 after purchasing an additional 927 shares during the period. Achmea Investment Management B.V. lifted its stake in shares of CVS Health by 87.1% in the 2nd quarter. Achmea Investment Management B.V. now owns 244,724 shares of the pharmacy operator’s stock valued at $16,881,000 after purchasing an additional 113,914 shares during the last quarter. Finally, Cetera Trust Company N.A boosted its holdings in shares of CVS Health by 6.3% in the 2nd quarter. Cetera Trust Company N.A now owns 12,268 shares of the pharmacy operator’s stock worth $846,000 after purchasing an additional 725 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 2.3%

NYSE CVS opened at $78.69 on Friday. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15. The company’s 50-day moving average price is $78.53 and its 200-day moving average price is $77.50. The stock has a market cap of $100.11 billion, a PE ratio of 57.02, a PEG ratio of 0.84 and a beta of 0.49. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. CVS Health’s payout ratio is 192.75%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native consumer health technology subsidiary, and announced a strategic partnership with Google Cloud to build an integrated, AI-powered consumer engagement platform that aggregates data across payers, pharmacies and providers — a move that could boost customer retention, digital revenue and care coordination over time. Read More.
• Neutral Sentiment: Major business press and financial outlets are highlighting the partnership and platform rollout (coverage from Reuters, Forbes, FierceHealthcare and others), increasing visibility but leaving questions about monetization timing and near-term earnings impact. Read More.
• Neutral Sentiment: Investors are also revisiting valuation after a strong one‑year gain; articles assessing whether CVS remains attractive suggest the market is weighing growth potential from Health100 against its current multiples and recent guidance. Read More.
• Negative Sentiment: Regulatory risk: CVS warned that proposed Tennessee legislation banning single companies from owning both pharmacies and PBMs could force the company to close 134 retail pharmacies in that state — a concrete near‑term operational and revenue risk if the bill advances. Read More.
• Negative Sentiment: Analyst pressure: Wolfe Research trimmed its price target on CVS, which can amplify selling pressure even as management emphasizes strategic investments and guidance. Read More.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Morgan Stanley increased their target price on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. Argus cut their price target on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Finally, Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $99.00) on shares of CVS Health in a research report on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $94.91.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.